Chiron Refining GMP Remediation Plan Following FDA Warning Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
The FDA letter requests additional information on "investigations into cGMP deviations and the design and conduct of studies to aid investigations," Chiron says. The letter follows an inspection of Chiron's Liverpool facility where Fluvirin is produced.
You may also be interested in...
Chiron To Meet With U.K. Regulatory Authorities On Fluvirin Suspension
The company does not anticipate the three-month manufacturing suspension will be lifted following the Oct. 6 meeting. Chiron's projected 48 mil. doses of flu vaccine were expected to account for nearly 50% of the U.S. supply.
Chiron Response To FDA "483" Report For Fluvirin Plant Expected In Early August
FDA issued its observations following a nine-day inspection of the company's Liverpool, U.K. manufacturing facility in mid-July.
Chiron Response To FDA "483" Report For Fluvirin Plant Expected In Early August
FDA issued its observations following a nine-day inspection of the company's Liverpool, U.K. manufacturing facility in mid-July.